Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Statistical Methods for Analyzing Epidemiological Data01:25

Statistical Methods for Analyzing Epidemiological Data

Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Pulmonary Function Tests01:25

Pulmonary Function Tests

Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset.

NPJ Parkinson's disease·2026
Same author

Association Between Furosemide and Risk of Parkinson's Disease in a Nested Case-Control Study.

Basic & clinical pharmacology & toxicology·2026
Same author

Multi-locus genetic dosage shapes cognitive disease progression in Parkinson's patients: 15-year meta-analysis of 24 cohorts.

NPJ Parkinson's disease·2026
Same author

Revisiting the Association Between Calcium Channel Blockers and Parkinson's Disease in the E3N Cohort.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Genome-wide association study of copy number variations in Parkinson's disease.

NPJ Parkinson's disease·2026
Same author

Identifying Drugs Associated With Parkinson's Disease Risk Using Machine Learning.

Basic & clinical pharmacology & toxicology·2026

Related Experiment Videos

Why does lung function predict mortality? Results from the Whitehall II Cohort Study.

Séverine Sabia1, Martin Shipley, Alexis Elbaz

  • 1INSERM, U1018, Centre for Research in Epidemiology and Population Health, Hôpital Paul-Brousse, 16 avenue Paul Vaillant Couturier, Bâtiment 15/16, F-94807, Villejuif, France. Severine.Sabia@inserm.fr

American Journal of Epidemiology
|October 22, 2010
PubMed
Summary

Poor lung function significantly increases mortality risk. Inflammatory markers, cardiovascular diseases, and lifestyle factors partially explain this link, with inflammation being a key mediator.

Related Experiment Videos

Area of Science:

  • Epidemiology
  • Respiratory Medicine
  • Public Health

Background:

  • Poor lung function is linked to increased mortality.
  • The mediating factors for this association require further elucidation.

Purpose of the Study:

  • To investigate the extent to which various factors explain the association between reduced lung function and mortality.
  • To identify key mediating pathways, including socioeconomic position, behavior, cardiovascular risk factors, inflammatory markers, and chronic diseases.

Main Methods:

  • Analysis of data from 4,817 Whitehall II Study participants (mean age 60.8 years).
  • Lung function measured using Forced Expiratory Volume in 1 second (FEV1) / height squared (FEV1/ht²).
  • Mortality data collected over a mean follow-up of 6.4 years.

Main Results:

  • Lowest tertile of FEV1/ht² was associated with a 1.92-fold increased mortality risk (adjusted for age and sex).
  • Inflammatory markers explained 21.3% of the FEV1/ht²-mortality association.
  • Cardiovascular diseases (coronary heart disease, stroke, diabetes) explained 11.7%, and lifestyle factors explained 9.8%.

Conclusions:

  • Inflammatory markers are a significant mediator between poor lung function and mortality.
  • Cardiovascular diseases and lifestyle factors also contribute to this association.
  • These factors collectively explained 32.5% of the observed lung function-mortality link.